To ask Her Majesty's Government, further to the Written Answer by Baroness Verma on
16 June (WA 23–24) on energy prices, what assessment they have made of the time needed
for suppliers to develop a conditional Contracts for Difference (CfD) powerpurchase
agreement (PPA), for it to undergo an internal credit approval process, to be negotiated
competitively with independent generators, and to be assessed by the generator's putative
financiers before they can offer finance terms to independent generators; and what
impact they consider that timeframe will have on conditional PPAs being agreed prior
to the first allocation round of CfDs.
<p>We anticipate that some generators will seek to establish the terms of any PPA
and financing arrangements before they participate in the CfD allocation round, in
order to understand better their likely costs. Agreements between generators and PPA
providers could take a number of different forms, from indicative terms to a signed
contract. The decision to sign a conditional PPA ahead of the auction, and the duration
of any agreement, are ultimately commercial matters.</p><p>We anticipate that the
Offtaker of Last Resort (OLR) will encourage competition in the PPA market both at
the outset of the CfD and once any initial PPA has expired. Generators agreeing to
a conditional PPA would be able to participate in the later short-term PPA market,
once their initial PPA had expired; backed by the protections afforded by the OLR.</p><p>
</p>
To ask Her Majesty's Government, in each year since 2010, what was the (1) total number
of, and (2) net ingredient cost of, each type of contraceptive and contraceptive device
dispensed in (a) community clinics, and (b) general practice, in each clinical commissioning
group and local authority area in England.
<p>Information is not held centrally on the numbers or cost of contraceptives supplied
direct to patients through community clinics or general practices.</p>
To ask Her Majesty's Government, in each year since 2010, how many prescriptions were
written for (1) oral contraceptives, (2) intrauterine systems for the purpose of contraception,
(3) contraceptive injections, (4) contraceptive sub-dermal implants, (5) emergency
hormonal contraceptives, and (6) intrauterine devices for the purpose of emergency
contraception, in each clinical commissioning group area.
<p>Information is not collected centrally on the number of prescriptions written.
However, information is available on the number of prescription items dispensed.</p><p>
</p><p>A series of tables representing the four financial years 2010-11 to 2013-14,
have been placed in the Library. These provide information on each of the categories
of contraceptives requested, apart from intrauterine devices for the purpose of emergency
contraception, as information is not held on whether intrauterine devices are for
emergency or non-emergency use, however, totals for all intrauterine devices are included
within the category of intrauterine systems for the purpose of contraception.</p><p>
</p><p>The tables are based on ePACT data, representing prescriptions written in England
and dispensed in the community in the United Kingdom. This does not include supply
through community clinics. Information is not available for Q1 of 2010. Commissioning
care group areas were formed in April 2013. Information prior to this time is in the
form of primary care trusts. Contraceptives are defined products listed within British
National Formulary (BNF) Section 7.3 <em>Contraceptives</em>.</p>